Therapeutics

22/647 → 18/1165; -1.86 percentage points of formation share.

What stands out about this batch of "Therapeutics" companies is how narrow and mechanism-specific each bet has become, rather than chasing broad disease categories. Instead of one company per major illness, you get several teams attacking the same organ or pathway from different angles: Ochre Bio and Altay Therapeutics both work on chronic liver disease, one through RNA medicines and the other through small molecules, while Nephrogen goes after kidney and pancreatic conditions with gene therapy specifically because no curative option exists yet for either. The platform-versus-product split is also visible, with Catena Biosciences and PipeBio building tools and infrastructure that other therapeutics companies would use, rather than drugs themselves, alongside Biodock doing the same for microscopy analysis. This overall formation is cooling at 0.45x, matching Biotech's 0.46x and Cancer Therapeutics' identical 0.45x, but that stagnation looks strange next to Oncology, a statistically related formation growing at 3.08x, suggesting capital is rotating toward cancer-specific framing even as general therapeutics platforms lose relative share. Much of this specificity became viable only after mRNA delivery and manufacturing techniques, proven out during the COVID vaccine effort in 2020 and 2021, gave smaller teams like Kernal Bio and Sensible Biotechnologies a template for building targeted therapeutic platforms without needing pharma-scale infrastructure. The result is a field of founders building narrow, defensible biological tools rather than broad cures, betting that owning one mechanism well beats chasing a whole disease category.

No comparable outside activity is connected yet.

These share a word with “Therapeutics” but are tracked as separate categories. The real overlap below is the actual share of Therapeutics’s companies also found in that category — not a guess.